Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2023 | Sequencing of therapies to improve outcomes of CLL patients

Martina Seiffert • 8 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia Antibodies CAR-T Checkpoint inhibitors

Martina Seiffert, PhD, German Cancer Research Center, Heidelberg, Germany, discusses the necessity of sequencing and combining therapies rationally in patients with chronic lymphocytic leukemia (CLL) to ensure T-cell activation, in order to improve outcomes of patients receiving immune checkpoint or CAR T-cell therapies. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Martina Seiffert

1:08
Combining CAR-T with T cell-engaging bispecific antibodies to enhance efficacy in CLL murine models
Martina Seiffert • 8 Oct 2023
0:57
Anti-tumor immunity in the lymphoid microenvironment
Martina Seiffert • 8 Oct 2023
6:40
Looking beyond the leukemic cell for answers
Christopher Pepper et al. • 12 May 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals